Bausch Health Cos (NYSE:BHC) Insider Aimee Lenar Sells 36,827 Shares

Posted by Francis Steltz on Aug 21st, 2026

Bausch Health Cos Inc. (NYSE:BHC – Get Free Report) insider Aimee Lenar sold 36,827 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the transaction, the insider directly owned 334,853 shares in the company, valued at $2,354,016.59. This trade represents a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Price Performance

Shares of NYSE:BHC opened at $6.84 on Friday. Bausch Health Cos Inc. has a 12 month low of $4.33 and a 12 month high of $8.00. The firm has a market capitalization of $2.56 billion, a P/E ratio of -2.31 and a beta of 0.38. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.44 and a quick ratio of 1.08. The company’s fifty day moving average price is $5.33 and its 200 day moving average price is $5.46.

Bausch Health Cos (NYSE:BHC – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. As a group, sell-side analysts predict that Bausch Health Cos Inc. will post 4.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Zacks Research downgraded Bausch Health Cos from a “hold” rating to a “strong sell” rating in a research note on Friday, July 24th. Royal Bank Of Canada decreased their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Jefferies Financial Group upgraded shares of Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $8.00.

Read Our Latest Stock Analysis on Bausch Health Cos

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Tidal Investments LLC raised its stake in Bausch Health Cos by 2.6% in the 2nd quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after purchasing an additional 1,276 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Bausch Health Cos by 14.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock worth $98,000 after buying an additional 1,812 shares in the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Bausch Health Cos during the second quarter worth about $148,000. Pictet Asset Management Holding SA raised its position in shares of Bausch Health Cos by 4.1% in the first quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock valued at $292,000 after buying an additional 2,114 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock valued at $690,000 after buying an additional 2,552 shares during the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Cos Company Profile

(Get Free Report)

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.